Acutus Medical Inc (AFIB) Peer Comparison
$0.00
$-0.03
(-99.67%)
As on 03-Sep-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$20 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Edit
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 12,650 | 12,007 | 10,638 | 9,762 |
Revenue ($ Mln) |
20 | 1,505 | 6,164 | 613 | 2,589 |
Net Profit ($ Mln) |
-9.55 | 160.59 | 625.00 | -188.05 | 222.40 |
Net Margin (%) |
-47.36 | 10.67 | 5.41 | -30.68 | 8.59 |
RoE (%) |
153.11 | 10.86 | 11.84 | -28.10 | 3.04 |
Price to Earnings |
-- | 79.29 | 19.52 | -- | 44.47 |
Price-To-Book |
0.16 | 8.31 | 2.34 | 15.27 | 1.36 |
Income Statement ($ Mln)
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
20.16 | 1,194.62 | 5,810.00 | 383.48 | 2,566.50 |
|
Cost of Revenue
|
19.14 | 439.62 | 1,731.00 | 94.03 | 1,187.60 |
|
Gross Profit
|
1.01 | 755.00 | 4,079.00 | 289.45 | 1,378.90 |
|
Operating Expenses
|
1.07 | 668.77 | 3,422.00 | 411.82 | 1,109.90 |
|
Operating Profit (EBIT)
|
-0.06 | 86.22 | 657.00 | -122.37 | 269.00 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-4.54 | 20.87 | 498.00 | -145.60 | -2,342.50 |
|
Provision for Tax
|
0.01 | 6.86 | 86.00 | 0.77 | -498.30 |
|
Profit after Tax (Net Income)
|
-9.55 | 14.01 | 412.00 | -146.37 | -1,844.20 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | 14.01 | 412.00 | -- | -- |
Liabilities ($ Mln)
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-11.59 | 1,150.93 | 5,265.00 | 766.93 | 6,569.30 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
27.80 | 223.91 | 3,558.00 | 132.70 | 2,327.00 |
|
Current Liabilities
|
12.44 | 158.35 | 1,531.00 | 75.13 | 467.80 |
|
Total Liabilities
|
28.65 | 1,533.18 | 10,354.00 | 974.76 | 9,364.10 |
Assets ($ Mln)
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3.07 | 582.06 | 5,933.00 | 524.96 | 6,333.80 |
|
Current Assets
|
25.58 | 951.13 | 4,421.00 | 449.79 | 3,030.30 |
|
Total Assets
|
28.65 | 1,533.18 | 10,354.00 | 974.76 | 9,364.10 |
|
Total Debt*
|
35.76 | 223.39 | 3,321.00 | 103.40 | 1,374.70 |
|
Net Current Assets
|
13.14 | 792.78 | 2,890.00 | 374.67 | 2,562.50 |
Cashflow ($ Mln)
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-31.66 | 168.48 | 987.00 | -61.32 | 455.20 |
|
Cash Flow from Investing Activities
|
22.15 | 77.62 | -569.00 | 47.83 | -160.20 |
|
Cash from Financing Activities
|
-2.89 | -87.01 | -86.00 | 91.54 | -218.80 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-30.91 | 1.01 | 4.88 | -17.06 | -20.39 |
|
ROE (%)
|
153.11 | 1.20 | 7.86 | -23.83 | -24.09 |
|
ROA (%)
|
-23.11 | 0.91 | 4.05 | -15.29 | -17.03 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-47.36 | 1.17 | 7.09 | -38.17 | -71.86 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.81 | 0.13 | 0.05 | 0.22 | -0.04 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
88.31 | -84.59 | 56.65 | -8.70 | -189.37 |
|
EPS Growth (%)
|
0.88 | -0.85 | 2.11 | 0.04 | -1.98 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.17 | 665.53 | 26.24 | -56.94 | -4.94 |
|
Price / Book Value
|
-0.14 | 8.10 | 2.05 | 10.87 | 1.39 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
10.40 | 200.24 | 10.12 | -84.89 | -4.12 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-3.09 | 0.19 | 0.63 | 0.13 | 0.21 |
|
Short term debt to equity ratio
|
-0.69 | 0.01 | 0.01 | 0.00 | 0.01 |
|
Current Ratio
|
2.06 | 6.01 | 2.89 | 5.99 | 6.48 |
|
Quick Ratio
|
1.91 | 3.44 | 1.33 | 5.22 | 4.85 |
|
Interest Coverage
|
0.21 | 15.72 | 5.90 | -13.50 | -46.90 |
Operating Efficiency Ratios
| Acutus Medical Inc (AFIB) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
39.08 | 14.04 | 20.77 | 15.84 | 17.63 |
|
Asset Turnover
|
0.49 | 0.77 | 0.57 | 0.40 | 0.24 |
|
Receivable days
|
174.24 | 56.48 | 71.23 | 47.91 | 66.99 |
|
Inventory Days
|
57.89 | 330.16 | 504.51 | 193.57 | 236.89 |
|
Payable days
|
38.51 | 24.29 | 221.34 | 51.40 | 41.04 |
|
Cash Conversion Cycle
|
193.61 | 362.34 | 354.40 | 190.08 | 262.84 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
